MétaCan
Menu
Back to cohort
Record W4200283079 · doi:10.1212/wnl.0000000000013139

Predicting Outcome in Guillain-Barré Syndrome

2021· article· en· W4200283079 on OpenAlexaff
Alex Y. Doets, Hester F. Lingsma, Christa Walgaard, Badrul Islam, Nowshin Papri, Amy Davidson, Yuko Yamagishi, Susumu Kusunoki, Mazen M. Dimachkie, Waqar Waheed, Noah Kolb, Zhahirul Islam, Quazi Deen Mohammad, Thomas Harbo, Søren H. Sindrup, Govindsinh Chavada, Hugh J. Willison, Carlos Casasnovas, Kathleen Bateman, James Miller, Bianca van den Berg, Christine Verboon, Joyce Roodbol, Sonja E. Leonhard, Luana Benedetti, Satoshi Kuwabara, Peter Van den Bergh, Soledad Monges, Girolama Alessandra Marfia, Nortina Shahrizaila, Giuliana Galassi, Yann Péréon, J. Bürmann, Krista Kuitwaard, R. P. Kleyweg, Cintia Marchesoni, María J. Sedano Tous, Luís Querol, Isabel Illa, Yuzhong Wang, Eduardo Nobile‐Orazio, Simon Rinaldi, Angelo Schenone, J. Marín Pardo, Frédérique H Vermeij, Helmar C. Lehmann, Volkan Granit, Guido Cavaletti, Gerardo Gutiérrez‐Gutiérrez, Fábio Barroso, Leo H. Visser, Hans Katzberg, Efthimios Dardiotis, Shahram Attarian, Anneke J. van der Kooi, Filip Eftimov, Paul W. Wirtz, Johnny P.A. Samijn, H. Jacobus Gilhuis, Robert D. M. Hadden, James K. L. Holt, Kazim A. Sheikh, Summer Karafiath, Michal Vytopil, Giovanni Antonini, Thomas E. Feasby, Catharina G. Faber, C.J. Gijsbers, Mark Busby, Rhys Roberts, Nicholas J. Silvestri, Raffaella Fazio, Gert W. van Dijk, Marcel P.J. Garssen, C.S.M. Straathof, Kenneth C. Gorson, Bart C. Jacobs, Richard AC Hughes, David R. Cornblath, H.‐P. Hartung, Pieter A. van Doorn, L.C. de Koning, M. van Woerkom, Melissa R. Mandarakas, BHIthSci MPhty, Ricardo Reisin, Stephen Reddel, Paolo Ripellino, Sung‐Tsang Hsieh, Jean Addington, Senda Ajroud‐Driss, Henning Andersen, Umesh A. Badrising, I.R. Bella, T. E. Bertoríni, R. Bhavaraju-Sanka, Mariangela Bianco, Thomas H. Brannagan, Chiara Briani, S. Butterworth, Chi‐Chao Chao, Shiping Chen, Kristl G. Claeys, M.E. Conti, Jeremy Cosgrove, Marinos C. Dalakas, Charlotta Dornonville de la Cour, Andoni Echaniz‐Laguna, Janev Fehmi, C. Fokke, T. Fujioka, E. Fulgenzi, Tania García‐Sobrino, James M. Gilchrist, Jonathan Goldstein, Namita Goyal, Stefano Grisanti, L. Gutman, Jakob Vormstrup Holbech, Christian Homedes, M. Htut, Korné Jellema, I. Jericó Pascual, María Concepción Jimeno-Montero, Kenichi Kaida, Mohammad Khoshnoodi, Lynette Kiers, Kurt Kimpinski, A Köhler, Norito Kokubun, Motoi Kuwahara, Jing Yi Kwan, Shafeeq Ladha, Lisbeth Lassen, V. Lawson, E.B. Lee Pan, Luciana León Cejas, Michael P. Lunn, Armelle Magot, Hadi Manji, Celedonio Márquez‐Infante, L. Aguilar, Eugenia Martínez‐Hernández, Giorgia Mataluni, Marcelo Mattiazzi, Christopher McDermott, Gregg Meekins, Caterina Nascimbene, R.J. Nowak, M. Osei-Bonsu, Robert M. Pascuzzi, Valeria Prada, I. Rojas-Marcos, Stacy A. Rudnicki, George Sachs, Makoto Samukawa, L. Santoro, A. Savransky, Lenka Schwindling, Yukari Sekiguchi, Claudia Sommer, Alex C. Spyropoulos, Beth E. Shubin Stein, Amro Stino, Chong Yew Tan, Hatice Tankişi, Paul Twydell, Philip Van Damme, T. van der Ree, Rinske van Koningsveld, J.D. Varrato, Chao Xing, Lan Zhou, Saša Živković

Bibliographic record

VenueNeurology · 2021
Typearticle
Languageen
FieldMedicine
TopicPeripheral Neuropathies and Disorders
Canadian institutionsUniversity of TorontoUniversity of CalgaryUniversity Health Network
FundersUCB PharmaFogarty International CenterInstituto de Salud Carlos IIIAstellas PharmaPrinses Beatrix SpierfondsGeneralitat de CatalunyaSanofiEuropean CommissionDepartament de Salut, Generalitat de CatalunyaGrifolsGBS/CIDP Foundation InternationalSeventh Framework ProgrammeBaxaltaEli Lilly and CompanyCSL BehringMedical Research CouncilBiogenCelgeneAlnylam PharmaceuticalsAlexion PharmaceuticalsNational Institutes of HealthArgenx
KeywordsGuillain-Barre syndromeMedicineOutcome (game theory)PediatricsMathematics

Abstract

fetched live from OpenAlex

BACKGROUND AND OBJECTIVES: The clinical course and outcome of the Guillain-Barré syndrome (GBS) are diverse and vary among regions. The modified Erasmus GBS Outcome Score (mEGOS), developed with data from Dutch patients, is a clinical model that predicts the risk of walking inability in patients with GBS. The study objective was to validate the mEGOS in the International GBS Outcome Study (IGOS) cohort and to improve its performance and region specificity. METHODS: We used prospective data from the first 1,500 patients included in IGOS, aged ≥6 years and unable to walk independently. We evaluated whether the mEGOS at entry and week 1 could predict the inability to walk unaided at 4 and 26 weeks in the full cohort and in regional subgroups, using 2 measures for model performance: (1) discrimination: area under the receiver operating characteristic curve (AUC) and (2) calibration: observed vs predicted probability of being unable to walk independently. To improve the model predictions, we recalibrated the model containing the overall mEGOS score, without changing the individual predictive factors. Finally, we assessed the predictive ability of the individual factors. RESULTS: For validation of mEGOS at entry, 809 patients were eligible (Europe/North America [n = 677], Asia [n = 76], other [n = 56]), and 671 for validation of mEGOS at week 1 (Europe/North America [n = 563], Asia [n = 65], other [n = 43]). AUC values were >0.7 in all regional subgroups. In the Europe/North America subgroup, observed outcomes were worse than predicted; in Asia, observed outcomes were better than predicted. Recalibration improved model accuracy and enabled the development of a region-specific version for Europe/North America (mEGOS-Eu/NA). Similar to the original mEGOS, severe limb weakness and higher age were the predominant predictors of poor outcome in the IGOS cohort. DISCUSSION: mEGOS is a validated tool to predict the inability to walk unaided at 4 and 26 weeks in patients with GBS, also in countries outside the Netherlands. We developed a region-specific version of mEGOS for patients from Europe/North America. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the mEGOS accurately predicts the inability to walk unaided at 4 and 26 weeks in patients with GBS. TRIAL REGISTRATION INFORMATION: NCT01582763.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.006
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.269
Teacher spread0.251 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations67
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueNeurologySame topicPeripheral Neuropathies and DisordersFrench-language works237,207